# Advances in the application strategies of CRISPR/Cas9 technology in chimeric antigen receptor T cell therapy for hematological malignancies

## TL;DR

This paper explores how CRISPR/Cas9 can improve CAR-T cell therapy for blood cancers by making it more efficient and broadly applicable.

## Contribution

The paper highlights recent advances in using CRISPR/Cas9 to optimize CAR-T cell therapy, including strategies for universal CAR-T cells and improved editing precision.

## Key findings

- CRISPR/Cas9 enables the development of universal CAR-T cells that can be used across multiple patients.
- Recent strategies enhance the precision and safety of CRISPR/Cas9 in CAR-T cell engineering.
- CRISPR/Cas9 is being applied to expand CAR-T therapy to T-cell and myeloid leukemias.

## Abstract

嵌合抗原受体T细胞（CAR-T细胞）疗法在复发难治性B细胞恶性肿瘤治疗中取得了突破性进展，但仍面临制备复杂、适应证局限、细胞耗竭及疗效不持久等挑战。CRISPR/Cas9作为一种高效、相对简单的基因编辑技术，为突破这些瓶颈提供了新的可能。本文简述CRISPR/Cas9的工作机制，重点探讨其在开发通用型CAR-T细胞、增强T细胞功能及拓展CAR-T细胞至T系和髓系白血病治疗中的最新应用与临床实践。此外，本文聚焦近两年用于提高CRISPR/Cas9系统的编辑精准性、递送效率和安全性的优化策略，以期为CAR-T细胞疗法的优化设计和临床应用提供参考。